Therefore, FLT3-ITD is the leukemogenic driver for this model, and the observed in vivo anti-AML activity of narazaciclib in this model likely resulted from its suppression of FLT3-ITD kinase activity30. Here, FLT3 is linked to acute myeloid leukemia.